Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

211 Mt. Airy Road
Basking Ridge, NJ 07920

Tel: (908) 992-6400

Visit website

NEWS

Business

Feeling Collaborative, Merck Inks Three More Deals to Strengthen Portfolio

Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.

October 25, 2021

4 min read

Alex Keown

BioMidwest

Clinical Catch-Up: September 20-24

There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.

September 24, 2021

12 min read

Mark Terry

Drug Development

Several Companies Tout Lung Cancer Breakthroughs at ESMO 2021

Lung cancer is a particularly difficult cancer to treat, but several companies presented very promising data at this year’s European Society of Medical Oncology (ESMO) Congress 2021.

September 20, 2021

4 min read

Mark Terry

Drug Development

Clinical Catch-Up: August 9-13

There was plenty of clinical trial updates last week. Here’s a look.

August 13, 2021

5 min read

Mark Terry

Drug Development

Notch Up Another Win for Enhertu, This One in Metastatic Breast Cancer

The clinical study compared Enhertu to Kadcyla in HER2+ metastatic breast cancer patients who previously received trastuzumab.

August 9, 2021

3 min read

Mark Terry

Policy

Judge Orders Novartis to Cough Up $178 Million to Plexxikon Over Patent Infringements

Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.

July 23, 2021

2 min read

Brandon May

Pharm Country

Pharm Country Hotbed Continues to Prove it is Home to a Hot Job Market

BioSpace’s Pharm Country Hotbed ranges from Connecticut, New York, New Jersey, Pennsylvania and Rhode Island.

July 9, 2021

5 min read

Mark Terry

Global Roundup: UK Expands Life Sciences Ecosystem with Formation of We Are Pioneering Group

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

April 28, 2021

10 min read

Alex Keown

FDA

Enhertu Snags FDA Approval for HER2-Positive Gastric Cancer Patients

Daiichi Sankyo’s and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) has become the first HER2-directed medication approved to treat gastric cancer in the U.S. in 10 years.

January 18, 2021

2 min read

Alex Keown

JOBS